Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986036 in healthy Japanese and non-Japanese subjects
NCT03198182Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2017
- Primary completion
- Sep 2017
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing BMS-986036 with Placebo (2 arms). Primary endpoints: Adverse Events at 42 days and Serious Adverse Events at 42 days. Started Jun 2017; status: completed.
02
Drugs
pegbelfermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03198182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03198182.